FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161840385> ?p ?o ?g. }

• W2161840385 endingPage "772" @default.
• W2161840385 startingPage "765" @default.
• W2161840385 abstract "<h3>Purpose</h3> Semicontinuous low-dose-rate teletherapy (SLDR) is a novel irradiation strategy that exploits the increased radiosensitivity of glial cells in a narrow range of reduced dose rate. We present the final report of a prospective Phase I/II study testing the feasibility of SLDR for the treatment of recurrent gliomas. <h3>Methods and Materials</h3> Patients with previously irradiated recurrent gliomas were enrolled from November 1993 to March 1998. Patients received SLDR, delivered 6 to 8 hours/day at a dose rate of 40 to 50 cGy/hour for a total dose of 30 to 35 Gy given over 12 days using a modified cobalt-60 treatment unit. Acute central nervous system toxicity after SLDR treatment was the primary endpoint. Overall survival was a secondary endpoint. <h3>Results</h3> Twenty patients were enrolled (14 World Health Organization Grade 4 glioma, 5 Grade 2 glioma, 1 ependymoma). No patients developed ≥Grade 3 central nervous system toxicity at 3 months without radiographic evidence of tumor progression. Overall survival after SLDR was 56% at 6 months, 28% at 12 months, and 17% at 24 months. One patient survived >48 months, and 1 patient survived >60 months after SLDR treatment. Re-resection before SLDR treatment significantly improved 1-year overall survival for all patients and patients with Grade 4 glioma. <h3>Conclusion</h3> The delivery of SLDR is feasible in patients with recurrent gliomas and resulted in improved outcomes for patients who underwent re-resection. There were 2 long-term survivors (>48 months). This pilot study supports the notion that reduced dose rate influences the efficacy and tolerance of reirradiation in the treatment of recurrent gliomas." @default.
• W2161840385 created "2016-06-24" @default.
• W2161840385 creator A5003515749 @default.
• W2161840385 creator A5034479560 @default.
• W2161840385 creator A5050216655 @default.
• W2161840385 creator A5055152231 @default.
• W2161840385 creator A5057121260 @default.
• W2161840385 date "2012-02-01" @default.
• W2161840385 modified "2023-10-14" @default.
• W2161840385 title "Semicontinuous Low-Dose-Rate Teletherapy for the Treatment of Recurrent Glial Brain Tumors: Final Report of a Phase I/II Study" @default.
• W2161840385 cites W104478369 @default.
• W2161840385 cites W1485654067 @default.
• W2161840385 cites W1523831942 @default.
• W2161840385 cites W1571317512 @default.
• W2161840385 cites W1970233937 @default.
• W2161840385 cites W1978275013 @default.
• W2161840385 cites W1981424747 @default.
• W2161840385 cites W1985664084 @default.
• W2161840385 cites W1987238939 @default.
• W2161840385 cites W1989837095 @default.
• W2161840385 cites W1990995664 @default.
• W2161840385 cites W1996308940 @default.
• W2161840385 cites W2002122037 @default.
• W2161840385 cites W2002727873 @default.
• W2161840385 cites W2004250687 @default.
• W2161840385 cites W2005055583 @default.
• W2161840385 cites W2015546551 @default.
• W2161840385 cites W2035722384 @default.
• W2161840385 cites W2039611104 @default.
• W2161840385 cites W2039856809 @default.
• W2161840385 cites W2044772744 @default.
• W2161840385 cites W2050956507 @default.
• W2161840385 cites W2051166342 @default.
• W2161840385 cites W2054949155 @default.
• W2161840385 cites W2055519675 @default.
• W2161840385 cites W2060066113 @default.
• W2161840385 cites W2062053094 @default.
• W2161840385 cites W2068363001 @default.
• W2161840385 cites W2078330015 @default.
• W2161840385 cites W2085873602 @default.
• W2161840385 cites W2086748272 @default.
• W2161840385 cites W2096287682 @default.
• W2161840385 cites W2097404323 @default.
• W2161840385 cites W2098740232 @default.
• W2161840385 cites W2099431242 @default.
• W2161840385 cites W2099888675 @default.
• W2161840385 cites W2103630928 @default.
• W2161840385 cites W2119680678 @default.
• W2161840385 cites W2119999819 @default.
• W2161840385 cites W2124905037 @default.
• W2161840385 cites W2156819972 @default.
• W2161840385 cites W2157741803 @default.
• W2161840385 cites W2158685521 @default.
• W2161840385 cites W2314733280 @default.
• W2161840385 cites W2324016316 @default.
• W2161840385 cites W2033719611 @default.
• W2161840385 cites W2408890315 @default.
• W2161840385 doi "https://doi.org/10.1016/j.ijrobp.2010.10.057" @default.
• W2161840385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21236600" @default.
• W2161840385 hasPublicationYear "2012" @default.
• W2161840385 type Work @default.
• W2161840385 sameAs 2161840385 @default.
• W2161840385 citedByCount "6" @default.
• W2161840385 countsByYear W21618403852012 @default.
• W2161840385 countsByYear W21618403852013 @default.
• W2161840385 countsByYear W21618403852015 @default.
• W2161840385 countsByYear W21618403852017 @default.
• W2161840385 countsByYear W21618403852020 @default.
• W2161840385 countsByYear W21618403852021 @default.
• W2161840385 crossrefType "journal-article" @default.
• W2161840385 hasAuthorship W2161840385A5003515749 @default.
• W2161840385 hasAuthorship W2161840385A5034479560 @default.
• W2161840385 hasAuthorship W2161840385A5050216655 @default.
• W2161840385 hasAuthorship W2161840385A5055152231 @default.
• W2161840385 hasAuthorship W2161840385A5057121260 @default.
• W2161840385 hasConcept C126322002 @default.
• W2161840385 hasConcept C141071460 @default.
• W2161840385 hasConcept C168563851 @default.
• W2161840385 hasConcept C203092338 @default.
• W2161840385 hasConcept C2776283816 @default.
• W2161840385 hasConcept C2778227246 @default.
• W2161840385 hasConcept C29730261 @default.
• W2161840385 hasConcept C502942594 @default.
• W2161840385 hasConcept C509974204 @default.
• W2161840385 hasConcept C71924100 @default.
• W2161840385 hasConceptScore W2161840385C126322002 @default.
• W2161840385 hasConceptScore W2161840385C141071460 @default.
• W2161840385 hasConceptScore W2161840385C168563851 @default.
• W2161840385 hasConceptScore W2161840385C203092338 @default.
• W2161840385 hasConceptScore W2161840385C2776283816 @default.
• W2161840385 hasConceptScore W2161840385C2778227246 @default.
• W2161840385 hasConceptScore W2161840385C29730261 @default.
• W2161840385 hasConceptScore W2161840385C502942594 @default.
• W2161840385 hasConceptScore W2161840385C509974204 @default.
• W2161840385 hasConceptScore W2161840385C71924100 @default.
• W2161840385 hasIssue "2" @default.
• W2161840385 hasLocation W21618403851 @default.
• W2161840385 hasLocation W21618403852 @default.

• next